A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Inclusion Criteria:
Exclusion Criteria:
Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening.
Have a prior or planned surgical treatment for obesity.
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity.
Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2).
Have had within the past 90 days before screening:
Have New York Heart Association Functional Classification Class IV congestive heart failure.
Have a history of chronic or acute pancreatitis.
Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
Villingen-Schwenningen, Baden-Wurttemberg 78048, Germany
Lingen, Lower Saxony 49808, Germany
Bialystok, Podlaskie Voivodeship 15-281, Poland
Bialystok, Podlaskie Voivodeship 15-435, Poland
Ruda Śląska, Silesian Voivodeship 41-709, Poland
Lodz, Łódź Voivodeship 90-338, Poland